<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the progress made in improving harm reduction services in Scotland during the era of interferon‐based treatment, the prevalence of hepatitis C infection had remained stubbornly high. The recent scale‐up of DAA therapy to PWID is hoped to bring a treatment‐as‐prevention benefit.
 <xref rid="liv14222-bib-0054" ref-type="ref">54</xref> While the roll‐out of DBS testing was effective at diagnosing infection, a substantial minority of the infected population remains undiagnosed. It has proven difficult to fully engage general practitioners in case‐finding initiatives, with awareness‐raising campaigns having limited success.
 <xref rid="liv14222-bib-0055" ref-type="ref">55</xref>, 
 <xref rid="liv14222-bib-0056" ref-type="ref">56</xref> However, it is hoped that the availability of DAAs within primary care and other community settings will increase treatment uptake as the utility of the new therapies is recognised.
</p>
